In patients with advanced recurrent breast cancer treated with everolimus and exemestane, the blood everolimus concentration in patients with the CYP3A4*22 allele was significantly higher than that in patients without the *22 allele (Pascual et al., 2017). This evidence concerns the gene CYP3A4 and breast cancer.